The Experts below are selected from a list of 1869 Experts worldwide ranked by ideXlab platform
Piamerete Jervoestorm - One of the best experts on this subject based on the ideXlab platform.
-
three year results following regenerative periodontal surgery of advanced intrabony defects with enamel matrix derivative alone or combined with a Synthetic Bone Graft
Clinical Oral Investigations, 2016Co-Authors: Thomas Hoffmann, Elyan Almachot, Jorg Meyle, Piamerete Jervoestorm, Soren JepsenAbstract:Objectives This study aims to compare the clinical outcomes of a combination of enamel matrix derivatives (EMD) and a Synthetic Bone Graft (biphasic calcium phosphate) with EMD alone in wide and deep one- and two-wall intrabony defects 36 months after treatment.
-
a multi centre randomized controlled clinical trial on the treatment of intra bony defects with enamel matrix derivatives Synthetic Bone Graft or enamel matrix derivatives alone results after 12 months
Journal of Clinical Periodontology, 2011Co-Authors: Jorg Meyle, Elyan Almachot, Piamerete Jervoestorm, Thomas J Hoffmann, Heinz Topoll, Bernd Heinz, Christian Meis, Peter Eickholz, Soren JepsenAbstract:Meyle J, Hoffmann T, Topoll H, Heinz B, Al-Machot E, Jervoe-Storm P-M, Meis C, Eickholz P, Jepsen S: A multi-centre randomized controlled clinical trial on the treatment of intra-bony defects with enamel matrix derivatives/Synthetic Bone Graft or enamel matrix derivatives alone: results after 12 months. J Clin Periodontol 2011; doi: 10.1111/j.1600-051X.2011.01726.x. Abstract Objectives: Comparison of the clinical and radiographic outcomes of a combination of enamel matrix derivatives (EMD) and a Synthetic Bone Graft (EMD/SBG) with EMD alone in wide (2 mm) and deep (4 mm) one- and two- wall intra-bony defects 12 months after treatment. Materials and Methods: Seventy-three patients with chronic periodontitis and one wide (2 mm) and deep (4 mm) intra-bony defect were recruited in five centres in Germany. During surgery, defects were randomly assigned to EMD/SBG (test) or EMD (control). Assessments at baseline, after 6 and 12 months included Bone sounding, attachment levels, probing pocket depths, bleeding on probing, and recessions. Changes in defect fill were recorded radiographically. Results: Both treatment modalities led to significant clinical improvements. In the EMD/SBG group a mean defect fill of 2.7 ± 1.9 mm was calculated, in the EMD group the defect fill was 2.8 ± 1.6 mm. A mean gain in clinical attachment of 1.7 ± 2.1 mm in the test group and 1.9 ± 1.7 mm in the control group after 1 year was observed. Radiographic analysis confirmed for both groups that deeper defects were associated with greater defect fill. Conclusion: The results show comparable clinical and radiographic outcomes following both treatment modalities 12 months after treatment.
-
clinical outcomes after treatment of intra bony defects with an emd Synthetic Bone Graft or emd alone a multicentre randomized controlled clinical trial
Journal of Clinical Periodontology, 2008Co-Authors: S Jepsen, Elyan Almachot, Thomas J Hoffmann, Heinz Topoll, Bernd Heinz, H Rengers, M Teich, Jorg Meyle, Piamerete JervoestormAbstract:Objectives: Comparison of the outcomes of a combination of an enamel matrix derivative and a Synthetic Bone Graft (EMD/SBC) with EMD alone in wide intra-bony defects. Material and Methods: Seventy-three patients with chronic periodontitis were recruited in five centres in Germany. All patients had one wide intra-bony defect of 4 mm. Surgical procedures involved microsurgical technique and the modified papilla preservation flap. After debridement, defects were randomly assigned to EMD/SBC (test) or EMD (control). Assessments at baseline and after 6 months included Bone sounding, attachment levels, probing pocket depths, bleeding on probing and recessions. Early wound-healing, adverse effects and patients' perceptions were also recorded. Results: Both treatment modalities led to significant clinical improvements. Change in Bone fill 6 months after surgery was 2.0 mm (± 2.1) in the test group and 2.1 mm (± 1.2) in the control group. A gain in clinical attachment of 1.3 mm (± 1.8) in the test group and 1.8 mm (± 1.6) in the control group was observed. One week after surgery, primary closure was maintained in 95% of the test sites and 100% of the control sites. No differences in patients' perceptions were found. Conclusion: The results of the present study showed similar clinical outcomes following both treatment modalities.
Soren Jepsen - One of the best experts on this subject based on the ideXlab platform.
-
three year results following regenerative periodontal surgery of advanced intrabony defects with enamel matrix derivative alone or combined with a Synthetic Bone Graft
Clinical Oral Investigations, 2016Co-Authors: Thomas Hoffmann, Elyan Almachot, Jorg Meyle, Piamerete Jervoestorm, Soren JepsenAbstract:Objectives This study aims to compare the clinical outcomes of a combination of enamel matrix derivatives (EMD) and a Synthetic Bone Graft (biphasic calcium phosphate) with EMD alone in wide and deep one- and two-wall intrabony defects 36 months after treatment.
-
a multi centre randomized controlled clinical trial on the treatment of intra bony defects with enamel matrix derivatives Synthetic Bone Graft or enamel matrix derivatives alone results after 12 months
Journal of Clinical Periodontology, 2011Co-Authors: Jorg Meyle, Elyan Almachot, Piamerete Jervoestorm, Thomas J Hoffmann, Heinz Topoll, Bernd Heinz, Christian Meis, Peter Eickholz, Soren JepsenAbstract:Meyle J, Hoffmann T, Topoll H, Heinz B, Al-Machot E, Jervoe-Storm P-M, Meis C, Eickholz P, Jepsen S: A multi-centre randomized controlled clinical trial on the treatment of intra-bony defects with enamel matrix derivatives/Synthetic Bone Graft or enamel matrix derivatives alone: results after 12 months. J Clin Periodontol 2011; doi: 10.1111/j.1600-051X.2011.01726.x. Abstract Objectives: Comparison of the clinical and radiographic outcomes of a combination of enamel matrix derivatives (EMD) and a Synthetic Bone Graft (EMD/SBG) with EMD alone in wide (2 mm) and deep (4 mm) one- and two- wall intra-bony defects 12 months after treatment. Materials and Methods: Seventy-three patients with chronic periodontitis and one wide (2 mm) and deep (4 mm) intra-bony defect were recruited in five centres in Germany. During surgery, defects were randomly assigned to EMD/SBG (test) or EMD (control). Assessments at baseline, after 6 and 12 months included Bone sounding, attachment levels, probing pocket depths, bleeding on probing, and recessions. Changes in defect fill were recorded radiographically. Results: Both treatment modalities led to significant clinical improvements. In the EMD/SBG group a mean defect fill of 2.7 ± 1.9 mm was calculated, in the EMD group the defect fill was 2.8 ± 1.6 mm. A mean gain in clinical attachment of 1.7 ± 2.1 mm in the test group and 1.9 ± 1.7 mm in the control group after 1 year was observed. Radiographic analysis confirmed for both groups that deeper defects were associated with greater defect fill. Conclusion: The results show comparable clinical and radiographic outcomes following both treatment modalities 12 months after treatment.
-
A multi‐centre randomized controlled clinical trial on the treatment of intra‐bony defects with enamel matrix derivatives/Synthetic Bone Graft or enamel matrix derivatives alone: results after 12 months
Journal of Clinical Periodontology, 2011Co-Authors: Jorg Meyle, Thomas J Hoffmann, Heinz Topoll, Bernd Heinz, Peter Eickholz, Eli Al-machot, Pia-merete Jervøe-storm, Christian Meiß, Soren JepsenAbstract:Meyle J, Hoffmann T, Topoll H, Heinz B, Al-Machot E, Jervoe-Storm P-M, Meis C, Eickholz P, Jepsen S: A multi-centre randomized controlled clinical trial on the treatment of intra-bony defects with enamel matrix derivatives/Synthetic Bone Graft or enamel matrix derivatives alone: results after 12 months. J Clin Periodontol 2011; doi: 10.1111/j.1600-051X.2011.01726.x. Abstract Objectives: Comparison of the clinical and radiographic outcomes of a combination of enamel matrix derivatives (EMD) and a Synthetic Bone Graft (EMD/SBG) with EMD alone in wide (2 mm) and deep (4 mm) one- and two- wall intra-bony defects 12 months after treatment. Materials and Methods: Seventy-three patients with chronic periodontitis and one wide (2 mm) and deep (4 mm) intra-bony defect were recruited in five centres in Germany. During surgery, defects were randomly assigned to EMD/SBG (test) or EMD (control). Assessments at baseline, after 6 and 12 months included Bone sounding, attachment levels, probing pocket depths, bleeding on probing, and recessions. Changes in defect fill were recorded radiographically. Results: Both treatment modalities led to significant clinical improvements. In the EMD/SBG group a mean defect fill of 2.7 ± 1.9 mm was calculated, in the EMD group the defect fill was 2.8 ± 1.6 mm. A mean gain in clinical attachment of 1.7 ± 2.1 mm in the test group and 1.9 ± 1.7 mm in the control group after 1 year was observed. Radiographic analysis confirmed for both groups that deeper defects were associated with greater defect fill. Conclusion: The results show comparable clinical and radiographic outcomes following both treatment modalities 12 months after treatment.
Joseph D Smucker - One of the best experts on this subject based on the ideXlab platform.
-
Comparison of Two Synthetic Bone Graft Products in a Rabbit Posterolateral Fusion Model.
The Iowa orthopaedic journal, 2020Co-Authors: Douglas C Fredericks, Emily B Petersen, Nicole M Grosland, Nicole A. Devries Watson, Katherine N. Gibson-corley, Joseph D SmuckerAbstract:The drawbacks of iliac crest autoGraft as Graft material for spine fusion are well reported. Despite continued modifications to improve Bone healing capacity, the efficacy of Synthetic Graft materials as stand-alone replacements remains uncertain. The rabbit posterolateral fusion model is an established environment for testing of fusion concepts. It offers the opportunity to obtain radiographic, biomechanical and histological data on novel fusion materials. The objective of this study was to compare the spine fusion capability of two Synthetic Bone Graft products in an established rabbit posterolateral spine fusion (PLF) model: Signafuse® Bioactive Bone Graft Putty and Actifuse® ABX.Bilateral intertransverse spine fusion was performed at the L5-L6 transverse processes (TPs) of New Zealand White rabbits using either Signafuse or Actifuse ABX as the Bone Graft material. Bone remodeling and spine fusion were assessed at 6 and 12 weeks using radiographic, biomechanical and histological endpoints.Fusion rate by manual palpation at 6 weeks was greater for Signafuse (33%) compared to Actifuse ABX (0%), and equivalent in both groups at 12 weeks (50%). Biomechanical fusion rate based on flexion-extension data was 80% in Signafuse group and 44% for Actifuse ABX. Histology revealed a normal healing response in both groups. MicroCT and histomorphometric data at 6 weeks showed greater new Bone formation in the Signafuse group compared to Actifuse ABX (p
-
A Prospective Study of the Safety and Efficacy of Transforaminal Lumbar Interbody Fusion with InQu Bone Graft Extender with 12-month Radiographic and Clinical Outcomes
Journal of Spine & Neurosurgery, 2019Co-Authors: Barrett S. Boody, Joseph D Smucker, Zachary H Goldstein, Jesse Caballero, Kyle Ridlen Bs, Sheetal Vinayek Bs, Willa R. Sasso, Rick C. SassoAbstract:Objective: Bone Graft extenders are frequently used in spinal surgery as an adjunctive tool to achieve bony fusion. Synthetic Bone Graft extenders have been developed in order to avoid the time and morbidities associated with harvesting iliac crest autoGraft. Different types of Synthetic Bone Graft extenders have been developed including both ceramic and polymer-based Grafts. There is little literature on the efficacy of polymer-based Synthetic Bone Graft extenders. We sought to study the effectiveness of a specific polymer-based Synthetic Bone Graft extender, InQu, in achieving fusion in transforaminal lumbar interbody fusion. Methods: This study was a prospective multicenter study which enrolled 21 patients with grade 1 spondylolisthesis and/or degenerative disc diseases and were treated with transforaminal lumbar interbody fusion with the use of InQu Bone Graft extender. We collected pre-and post-operative patient-reported outcomes at 12-months, using Visual analog score (VAS)-back, VAS-right leg, VAS-left leg, and Oswestry Disability Index v2.0. Interbody fusion was subjectively evaluated on CT-scan by using a previously described fusion scoring system. Results: All patients reported significant improvement in all four self-reported data scores from preoperative to 12-month follow up (all p
-
comparison of two Synthetic Bone Graft products in a rabbit posterolateral fusion model
The Iowa orthopaedic journal, 2016Co-Authors: Douglas C Fredericks, Emily B Petersen, Nicole Devries A Watson, Nicole M Grosland, Katherine N Gibsoncorley, Joseph D SmuckerAbstract:The drawbacks of iliac crest autoGraft as Graft material for spine fusion are well reported. Despite continued modifications to improve Bone healing capacity, the efficacy of Synthetic Graft materials as stand-alone replacements remains uncertain. The rabbit posterolateral fusion model is an established environment for testing of fusion concepts. It offers the opportunity to obtain radiographic, biomechanical and histological data on novel fusion materials. The objective of this study was to compare the spine fusion capability of two Synthetic Bone Graft products in an established rabbit posterolateral spine fusion (PLF) model: Signafuse® Bioactive Bone Graft Putty and Actifuse® ABX.Bilateral intertransverse spine fusion was performed at the L5-L6 transverse processes (TPs) of New Zealand White rabbits using either Signafuse or Actifuse ABX as the Bone Graft material. Bone remodeling and spine fusion were assessed at 6 and 12 weeks using radiographic, biomechanical and histological endpoints.Fusion rate by manual palpation at 6 weeks was greater for Signafuse (33%) compared to Actifuse ABX (0%), and equivalent in both groups at 12 weeks (50%). Biomechanical fusion rate based on flexion-extension data was 80% in Signafuse group and 44% for Actifuse ABX. Histology revealed a normal healing response in both groups. MicroCT and histomorphometric data at 6 weeks showed greater new Bone formation in the Signafuse group compared to Actifuse ABX (p <0.05), with no differences detected at 12 weeks. Histological fusion scores were greater in the Signafuse group at 6 and 12 weeks, indicated by higher degree structural remodeling and tendency towards complete bridging of the fusion bed compared to the Actifuse ABX group.Confirmed by several metrics, Signafuse outperformed Actifuse ABX as a standalone Synthetic Bone Graft in an established PLF model, demonstrating greater rates of Bone remodeling and spine fusion. The combination of 45S5 bioactive glass and biphasic HA/βTCP granules of Signafuse appear to provide greater Bone healing capability in comparison to the 0.8% silicate-substituted hydroxyapatite material of Actifuse ABX.
M Diefenbeck - One of the best experts on this subject based on the ideXlab platform.
-
radiographic and histological analysis of a Synthetic Bone Graft substitute eluting gentamicin in the treatment of chronic osteomyelitis
Journal of Bone and Joint Infection, 2019Co-Authors: J Ferguson, N Athanasou, M Diefenbeck, M McnallyAbstract:Introduction: Managing chronic osteomyelitis can be challenging and attention to the osseous dead-space left following resection is an important part of successful treatment. We assess radiographic Bone healing following implantation of a gentamicin-eluting Synthetic Bone Graft substitute (gBGS) used at chronic osteomyelitis (cOM) resection. We also describe histological carrier changes from biopsies in nine cases at various time points. Methods:This was a retrospective review of a prospectively collected consecutive series of 163 patients with Cierny-Mader Type III or IV cOM who underwent single-stage excision, insertion of gBGS and definitive soft-tissue closure or coverage. Bone defect filling was assessed radiographically using serial radiographs. Nine patients had subsequent surgery, not related to infection recurrence, allowing opportunistic biopsy between 19 days and two years after implantation. Results: Infection was eradicated in 95.7% with a single procedure. 138 patients had adequate radiographs for assessment with minimum one-year follow-up (mean 1.7 years, range 1.0-4.7 years). Mean void-filling at final follow-up was 73.8%. There was significantly higher void-filling in metaphyseal compared to diaphyseal voids (mean 79.0% versus 65.6%; p=0.017) and in cases with good initial interdigitation of the carrier (mean 77.3% versus 68.7%; p=0.021). Bone formation continued for more than two years in almost two-thirds of patients studied (24/38; 63.2%). Histology revealed active biomaterial remodelling. It was osteoconductive with osteoblast recruitment, leading to the formation of osteoid, then woven and lamellar Bone on the substrate's surface. Immunohistochemistry demonstrated osteocyte specific markers, dentine matrix protein-1 and podoplanin within the newly formed Bone. Conclusion: This antibiotic-loaded biomaterial is effective in managing dead-space in surgically treated cOM with a low infection recurrence rate (4.3%) and good mean Bone void-filling (73.8%). The radiographic resolution of the Bone defect is associated with Bone formation, as supported by histological analysis.
-
establishment and effects of alloGraft and Synthetic Bone Graft substitute treatment of a critical size metaphyseal Bone defect model in the sheep femur
Apmis, 2019Co-Authors: W Hettwer, Peter Frederik Horstmann, Sabine Bischoff, Daniel Gullmar, Jurgen R Reichenbach, Martijn Van Griensven, Florian Gras, M DiefenbeckAbstract:Assessment of Bone Graft material efficacy is difficult in humans, since invasive methods like staged CT scans or biopsies are ethically unjustifiable. Therefore, we developed a novel large animal model for the verification of a potential transformation of Synthetic Bone Graft substitutes into vital Bone. The model combines multiple imaging methods with corresponding histology in standardized critical sized cancellous Bone defect. Cylindrical Bone voids (10 ml) were created in the medial femoral condyles of both hind legs (first surgery at right hind leg, second surgery 3 months later at left hind leg) in three merino‐wool sheep and either (i) left empty, filled with (ii) cancellous alloGraft Bone or (iii) a Synthetic, gentamicin eluting Bone Graft substitute. All samples were analysed with radiographs, MRI, μCT, DEXA and histology after sacrifice at 6 months. Unfilled defects only showed ingrowth of fibrous tissue, whereas good integration of the cancellous Graft was seen in the alloGraft group. The Bone Graft substitute showed centripetal biodegradation and new trabecular Bone formation in the periphery of the void as early as 3 months. μCT gave excellent insight into the structural changes within the defects, particularly progressive alloGraft incorporation and the Bone Graft substitute biodegradation process. MRI completed the picture by clearly visualizing soft tissue ingrowth into unfilled Bone voids and presence of fluid collections. Histology was essential for verification of trabecular Bone and osteoid formation. Conventional radiographs and DEXA could not differentiate details of the ongoing transformation process. This model appears well suited for detailed in vivo and ex vivo evaluation of Bone Graft substitute behaviour within large Bone defects.
-
radiographic and histological analysis of a Synthetic Bone Graft substitute eluting gentamicin in the treatment of chronic osteomyelitis a retrospective study in humans
Orthopaedic Proceedings, 2018Co-Authors: M Mcnally, M Diefenbeck, D Stubbs, N AthanasouAbstract:AimThis study describes and correlates the radiographic and histologic changes which develop in a Gentamicin-eluting Synthetic Bone Graft substitute* in the management of Bone defects after resection of chronic osteomyelitis (COM).Method100 patients with COM were treated with a single stage procedure, including management of the dead space with insertion of a Gentamicin-eluting Synthetic Bone Graft substitute*. Radiographs of 73 patients with a follow-up of at least 12 months (range 12–33 months) were available for review. Bone defects were diaphyseal in 32, metaphyseal in 34 and combined in 7 patients. In 3 patients, radiographs were not of sufficient quality to allow analysis.Five patients had subsequent surgery, not related to recurrence of infection, which allowed biopsy of the implanted material. These biopsies were harvested between 12 days and 9 months after implantation. Tissue was fixed in formalin and stained with haematoxylin-eosin and immunohistochemically for Bone matrix markers.ResultsRadiog...
-
radiographic and histological analysis of a Synthetic Bone Graft substitute eluting gentamicin in the treatment of chronic osteomyelitis a retrospective study in humans
Journal of Bone and Joint Surgery-british Volume, 2016Co-Authors: M Mcnally, M Diefenbeck, D Stubbs, N AthanasouAbstract:Aim This study describes and correlates the radiographic and histologic changes which develop in a Gentamicin-eluting Synthetic Bone Graft substitute[*][1] in the management of Bone defects after resection of chronic osteomyelitis (COM). Method 100 patients with COM were treated with a single stage procedure, including management of the dead space with insertion of a Gentamicin-eluting Synthetic Bone Graft substitute[*][1]. Radiographs of 73 patients with a follow-up of at least 12 months (range 12–33 months) were available for review. Bone defects were diaphyseal in 32, metaphyseal in 34 and combined in 7 patients. In 3 patients, radiographs were not of sufficient quality to allow analysis. Five patients had subsequent surgery, not related to recurrence of infection, which allowed biopsy of the implanted material. These biopsies were harvested between 12 days and 9 months after implantation. Tissue was fixed in formalin and stained with haematoxylin-eosin and immunohistochemically for Bone matrix markers. Results Radiographic: 31 of 34 diaphyseal implantations (91%) demonstrated remodelling of the biocomposite, gradually over many months, producing new Bone and resulting in a “normal post-osteomyelitic” appearance. In metaphyseal implantations, new Bone filled two-thirds or more of the defect in 55% of cases, one to two-thirds was filled in 31% and one third or less was filled in 14%. 22% of patients exhibited radiographic signs of dissolution and remodelling which are specific to this material. The ‘Halo’ sign of peripheral zone remodelling, the ‘Marble’ sign of dissolution and the ‘Puddle’ sign of distal migration can be described. Histologic: Histological assessment revealed early active remodelling of the biocomposite. The material was osteoconductive with accumulation of osteoblasts and osteoid and woven Bone formation on the surface of the Gentamicin-eluting Synthetic Bone Graft substitute[*][1] separated by fibrous tissue at the edge of the defect beneath reactive viable host Bone. Fibrous tissue contained a heavy macrophage infiltrate and the newly formed matrix contained the specific Bone proteins, dentine matrix protein-1 and podoplanin. There was limited evidence of remodelling into lamellar Bone at 20 weeks after implantation. Conclusions The Gentamicin-eluting Synthetic Bone Graft substitute[*][1] exhibits a specific pattern of radiographic change over many months after implantation. The resolution of the Bone defect would appear to be due to Bone formation, as seen in the histologic and immunohistochemical analysis. [1]: #fn-1
Mark J Kransdorf - One of the best experts on this subject based on the ideXlab platform.
-
Bone Graft materials and Synthetic substitutes
Radiologic Clinics of North America, 2006Co-Authors: Francesca D Beaman, Laura W Bancroft, Jeffrey J Peterson, Mark J KransdorfAbstract:Bone Graft materials quickly are becoming a vital tool in reconstructive orthopedic surgery and demonstrate considerable variability in their imaging appearance. Functions of Bone Graft materials include promoting osseous ingrowth and Bone healing, providing a structural substrate for these processes, and serving as a vehicle for direct antibiotic delivery. The three primary types of Bone Graft materials are alloGrafts, autoGrafts, and Synthetic Bone Graft substitutes.
